Eupraxia Pharmaceuticals Announces Additional Positive Clinical Data From Phase 1b/2a RESOLVE Trial Evaluating EP-104GI For Eosinophilic Esophagitis (EoE) - Press Release
Portfolio Pulse from Benzinga Newsdesk
Eupraxia Pharmaceuticals announced positive clinical data from its Phase 1b/2a RESOLVE trial evaluating EP-104GI for Eosinophilic Esophagitis (EoE). The trial's first and second cohorts showed potential efficacy up to 24 weeks, with the second cohort showing dose response improvements. The third cohort also showed improvements in patient-reported symptoms and histological outcomes at 12 weeks. EP-104GI demonstrated an encouraging safety profile across all cohorts.
May 21, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eupraxia Pharmaceuticals announced positive results from its Phase 1b/2a RESOLVE trial for EP-104GI, showing efficacy and safety across multiple cohorts. This could boost investor confidence and positively impact the stock price in the short term.
The positive clinical data from the RESOLVE trial, including efficacy and safety across multiple cohorts, is likely to boost investor confidence in Eupraxia Pharmaceuticals. This could lead to a short-term increase in the stock price as the market reacts to the promising trial results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100